Patents by Inventor Siddharth JINDAL

Siddharth JINDAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF
    Publication number: 20230235033
    Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.
    Type: Application
    Filed: October 7, 2022
    Publication date: July 27, 2023
    Inventors: Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
  • Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
    Patent number: 11498960
    Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 15, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini
  • POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF
    Publication number: 20200399351
    Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.
    Type: Application
    Filed: July 11, 2018
    Publication date: December 24, 2020
    Inventors: Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI